IL13 and irritable bowel syndrome: However, this hypothesis has suffered a setback as the result of two clinical trials have failed to demonstrate the efficacy of anti-IL-13 therapy (anrukinzumab and tralokinumab) in IBD patients, largely questioning a relevant role of IL-13 in driving IBD [49].